Jazz Pharmaceuticals JAZZ Equity income or loss
Equity income or loss at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's equity income or loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's equity income or loss?
- Jazz Pharmaceuticals (JAZZ) reported equity income or loss of $22.7M in Q4 2025.
- How has Jazz Pharmaceuticals's equity income or loss changed year-over-year?
- Jazz Pharmaceuticals's equity income or loss decreased by 49.7% year-over-year, from $45.12M to $22.7M.
- What is the long-term trend for Jazz Pharmaceuticals's equity income or loss?
- Over 2 years (2023 to 2025), Jazz Pharmaceuticals's equity income or loss has grown at a -23.1% compound annual growth rate (CAGR), from $153.66M to $90.79M.
- What does equity income or loss mean?
- The company's share of profits or losses from businesses it partially owns.
- How do you interpret equity income or loss?
- Positive values indicate profitable performance from equity-method investments, while negative values indicate losses.
- How does equity income or loss compare across companies?
- Common for companies with joint ventures or strategic minority stakes in other biopharma entities.